Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma - A study of the United Kingdom Children's Cancer Study Group

British Journal of Cancer

Volumn 96, Issue 3, 2007, Pages 424-431

  Veal, G J ^a   Cole, M ^a   Errington, J ^a   Pearson, A D J ^b   Foot, A B M ^c   Whyman, G ^d   Boddy, A V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

13 cis retinoic acid; Clinical pharmacology; Dosing; Drug metabolism; Isotretinoin

Indexed keywords

4 OXOISOTRETINOIN; DRUG METABOLITE; ISOTRETINOIN;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CHEILITIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG METABOLISM; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; SKIN TOXICITY;

ABSORPTION; ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; ISOTRETINOIN; MALE; NEUROBLASTOMA; OXIDATION-REDUCTION;

EID: 33846828405     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603554     Document Type: Article

References (23)

1. Adamson PC, Bailey J, Pluda J, Poplack DG, Bauza S, Murphy RF, Yarchoan R, Balis FM (1995) Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 13: 1238-1241
2. Adamson PC, Boylan JF, Balis FM, Murphy RF, Godwin KA, Gudas LJ, Poplack DG (1993) Time course of induction of metabolism of all-trans-retinoic acid and the upregulation of cellular retinoic acid-binding protein. Cancer Res 53: 472-476
3. Armstrong JL, Ruiz M, Boddy AV, Redfern CPF, Pearson ADJ, Veal GJ (2005) Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Brit J Cancer 92: 696-704
4. Beal S, Sheiner L (1989) NONMEM Users Guide - Part I Users Basic Guide. San Francisco, CA: NONMEM Project Group, UCSF
5. Chen H, Fantel AG, Juchau MR (2000) Catalysis of the 4-hydroxylation of retinoic acids by CYP3A7 in human fetal hepatic tissues. Drug Metab Dispos 28: 1051-1057
6. Colburn WA, Gibson DM, Wiens RE, Hanigan JJ (1983) Food increases the bioavailability of isotretinoin. J Clin Pharmacol 23: 534-539
7. Cole M, Price L, Parry A, Keir MJ, Pearson ADJ, Boddy AV, Veal GJ (2004) Estimation of glomerular filtration rate in paediatric cancer patients using (CR)-C-51-EDTA population pharmacokinetics. Brit J Cancer 90: 60-64
8. Finklestein JZ, Krailo MD, Lenarsky C, Ladisch S, Blair GK, Reynolds CP, Sitarz AL, Hammond GD (1992) 13-cis-retinoic acid (Nsc-122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy - report from the Childrens-Cancer-Study-Group. Med Pediatr Oncol 20: 307-311
9. Khan AA, Villablanca JG, Reynolds CP, Avramis VI (1996) Pharmacokinetic studies of 13-cis-retinoic add in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother Pharmacol 39: 34-41
10. Kohler JA, Imeson J, Ellershaw C, Lie SO (2000) A randomized trial of 13-cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Brit J Cancer 83: 1124-1127
11. Lanvers C, Reinhardt D, Dubbers A, Wagner-Bohn A, Creutzig U, Ritter J, Boos J (2003) Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia. Med Pediatr Oncol 40: 293-301
12. Matthay KK, Reynolds CP (2000) Is there a role for retinoids to treat minimal residual disease in neuroblastoma? Brit J Cancer 83: 1121-1123
13. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retinoic acid. New Engl J Med 341: 1165-1173
14. Muindi J, Frankel SR, Miller WH, Jakubowski A, Scheinberg DA, Young CW, Dmitrovsky E, Warrell RP (1992) Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations - implications for relapse and retinoid resistance in patients with acute promyelocytic leukemia. Blood 79: 299-303
15. Nadin L, Murray M (1999) Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol 58: 1201-1208
16. Reynolds CP, Kane DJ, Einhorn PA, Matthay KK, Crouse VL, Wilbur JR, Shurin SB, Seeger RC (1991) Response of neuroblastoma to retinoic acid in vitro and in vivo. In Advances in Neuroblastoma Research Evans AE, Dangio GJ, Knudson AG, and Seeger RC (eds). Vol 366, pp 203-211; Progress in Clinical and Biological Research, Wiley-Liss: New york
17. Rigas JR, Francis PA, Muindi JRF, Kris MG, Huselton C, Degrazia F, Orazem JP, Young CW, Warrell RP (1993) Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer I 85: 1921-1926
18. Savic R, Jonker D, Kerbusch T, Karlsson M (2004) Evaluation of a Transit Compartment Model Versus a Lag Time Model for Describing Drug Absorption Delay. Population Approach Group Europe: Uppsala, Sweden, pp 513
19. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD, Pittman KA, Spector S (1992) Analytical methods validation - bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Sci 81: 309-312
20. Sonneveld E, van den Brink CE, van der Leede BJM, Schulkes RKAM, Petkovich M, van der Burg B, van der Saag PT (1998) Human retionic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells. Cell Growth Differ 9: 629-637
21. Veal GJ, Errington J, Redfern CPF, Pearson ADJ, Boddy AV (2002) Influence of isomerisation on the growth inhibitory effects and cellular activity of 13-cis and all-trans retinoic acid in neuroblastoma cells. Biochem Pharmacol 63: 207-215
22. Villablanca JG, Khan AA, Avramis VI, Seeger RC, Matthay KK, Ramsay NK, Reynolds CP (1995) Phase I trial of 12-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation. J Clin Oncol 13: 894-901
23. Villani MG, Appierto V, Cavadini E, Valsecchi M, Sonnino S, Curley RW, Formelli F (2004) Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1. Clin Cancer Res 10: 6265-6275